Medifast Inc. MED
Packaged Foods · data as of November 13, 2026
Medifast Inc. (MED) is a consumer staples company listed in the US with a market value of about $145M. In the twelve months to September 30, 2026 it had revenue of $300M and net income of -$41M, a net margin of -13.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -16% a year, a 5-year average ROIC of 38%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 70% below the current price.
About Medifast
Medifast is listed in the US and classified in packaged foods. Revenue went from $285M in 2014 to $386M in 2025, growth of about 2.8% a year. It was profitable in 9 of the last 10 years in our data. Its share count fell by 3% over three years (buybacks). It spends 1% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- 5-year average ROIC above 12%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $300M | $386M | $602M | $1.1B | $1.6B | $1.5B | $935M | $714M | $501M | $302M | $275M |
| Net income | -$41M | -$19M | $2M | $99M | $144M | $164M | $103M | $78M | $56M | $28M | $18M |
| Free cash flow | -$4M | $1M | $17M | $141M | $178M | $60M | $139M | $74M | $56M | $40M | $22M |
| EPS (diluted) | $-3.69 | $-1.70 | $0.19 | $9.10 | $12.73 | $13.89 | $8.68 | $6.43 | $4.62 | $2.29 | $1.49 |
| Net margin | -13.6% | -4.8% | 0.4% | 9.3% | 9.0% | 10.8% | 11.0% | 10.9% | 11.1% | 9.2% | 6.5% |
| ROIC | — | -5.4% | 0.7% | 43.7% | 79.6% | 69.8% | 61.0% | 64.8% | 44.9% | 25.6% | 18.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Medifast stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 70% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Medifast pay a dividend?
Yes. The dividend yield is about 0.12%, and it has paid dividends for 10 years in our data.
Is Medifast a good stock to buy?
We do not give buy or sell advice. Medifast scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.